E Fund Management Co., Ltd. Seres Therapeutics, Inc. Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.33 - $5.07 $15,177 - $33,025	6,514 Added 15.67%	48,095 $114,000
Q2 2023 Aug 11, 2023	BUY	$4.67 - $6.55 $130,741 - $183,373	27,996 Added 206.08%	41,581 $199,000
Q1 2023 May 11, 2023	SELL	$4.95 - $6.09 $15,255 - $18,769	-3,082 Reduced 18.49%	13,585 $77,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $9.05 $13,218 - $23,502	2,597 Added 18.46%	16,667 $93,000
Q3 2022 Nov 14, 2022	BUY	$3.5 - $7.2 $49,245 - $101,304	14,070 New	14,070 $90,000

Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.62 $40,151 - $113,317	-14,871 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$6.3 - $8.84 $26,000 - $36,482	4,127 Added 38.41%	14,871 $106,000
Q4 2021 Feb 11, 2022	SELL	$6.02 - $11.43 $100,822 - $191,429	-16,748 Reduced 60.92%	10,744 $89,000
Q3 2021 Nov 12, 2021	BUY	$5.46 - $22.6 $114,681 - $474,690	21,004 Added 323.74%	27,492 $191,000
Q1 2021 May 12, 2021	BUY	$17.66 - $28.92 $114,578 - $187,632	6,488 New	6,488 $133,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.